Sains Malaysiana
49(1)(2020): 133-138
http://dx.doi.org/10.17576/jsm-2020-4901-16
Dinoprostone in First Trimester Miscarriages: A Prospective Observational Study
in a Malaysian Tertiary Healthcare Institution
Penggunaan Dinoprostone dalam Keguguran Trimester Pertama: Kajian Prospektif di Pusat Rujukan Perubatan di Malaysia
RAHANA
ABD RAHMAN, AZARISYAM AHMAD, IXORA KAMISAN ATAN & ZALEHA ABDULLAH MAHDY*
Department
of Obstetrics & Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak,
56000 Cheras, Kuala Lumpur, Federal Territory,
Malaysia
Diserahkan: 20 September 2019/Diterima: 11 Oktober 2019
ABSTRACT
The
objective of this paper was to evaluate the outcome of medical evacuation
of first trimester miscarriages using dinoprostone. A prospective observational study in a tertiary
centre between 1st January
and 31st December 2018 in Obstetrics and Gynaecology
unit, UKM Medical Centre. Women diagnosed with incomplete and missed
miscarriage (n=41) at or less than 13 weeks of gestation were recruited.
Dinoprostone 3 mg was inserted into the posterior fornix,
twice within 6 h apart on day-1 followed by similar protocol on
day-2. Patients were reassessed clinically and sonographically
upon passing out products of conception, at 48 h and day-7. Complete
evacuation was defined as closed cervical os
and/or endometrial thickness of less than 15 mm sonographically.
Treatment failure was defined as failure to achieve complete evacuation
by day-7. Overall success rate was 55.3% (n=26) being better in incomplete (n=6,
100%) as compared to missed miscarriage (n=21, 48.8%, p=0.03). Those
with successful evacuation required dinosprostone
at a mean of 8.4 ± 2.9
mg achieving
complete miscarriage within a mean of 27.8
± 16.6 h. Mean pain score was 5.8 ±
0.8 with mean patient satisfaction score of 8.7 ± 0.8. Mean drop in haemoglobin
was 0.7 ± 0.2
g/dL. No major adverse effects were reported. Medical evacuation of miscarriage using intravaginal
dinoprostone is safe and promising,
with acceptable success rate and high patient satisfaction. This
study supported previous studies suggesting presence of prostaglandin
E2 receptors in the first trimester.
Keywords: Dinoprostone;
first trimester miscarriage; medical evacuation
ABSTRAK
Tujuan kajian ini dijalankan adalah untuk menilai hasil penggunaan ubat untuk rawatan keguguran pada trimester pertama. Ini adalah kajian prospektif yang dijalankan di unit Obstetrik dan Ginekologi, Pusat Perubatan UKM dari 1 Januari hingga 31 Disember 2018. Semua pesakit (n=41) yang dikenal pasti mengalami keguguran pada atau kurang dari 13 minggu kandungan telah dimasukkan ke dalam kajian. Ubat dinoprostone 3 mg telah dimasukkan ke dalam faraj sebanyak 2 kali dalam beza masa selama 6 jam. Ini dilakukan selama 2 hari berturut-turut. Pesakit dinilai secara klinikal dan dengan menggunakan mesin imbasan jika ada perdarahan daripada faraj yang mengandungi tisu kandungan atau selepas 48 jam atau selepas 7 hari dari permulaan rawatan. Keguguran lengkap ditentukan apabila pintu rahim telah tertutup atau imbasan menunjukkan ketebalan dinding rahim kurang daripada 15 mm. Rawatan dianggap gagal jika keguguran lengkap tidak berlaku pada hari ketujuh selepas permulaan rawatan. Kejayaan keseluruhan adalah55.3% (n=26) dan ia adalah lebih baik dalam kes pesakit yang telah keguguran tidak lengkap (n=6, 100%) berbanding dengan mereka yang tiada langsung keguguran (n=21, 48.8%,
p=0.03). Mereka yang telah berjaya memerlukan dinosprostone pada min 8.4 ± 2.9 mg dan kejayaan dicapai pada min masa 27.8 ± 16.6 jam. Min skor kesakitan adalah5.8 ± 0.8 dan min kepuasan pesakit8.7 ± 0.8. Min penurunan hemoglobin adalah0.7 ± 0.2 g/dL. Tidak terdapat komplikasi yang teruk semasa kajian. Rawatan untuk keguguran dengan menggunakan ubat adalah
selamat dan mempunyai kadar kejayaan yang baik. Kebanyakan pesakit juga berpuas
hati. Ini membuktikan teori bahawa terdapat reseptor untuk prostaglandin E2 pada trimester pertama kandungan.
Kata kunci: Dinoprostone; evakuasi perubatan; keguguran trimester pertama
RUJUKAN
Al Inizi, S.A. & Ezimokhai, M. 2003. Vaginal misoprostol
versus dinoprostone for the management of missed abortion. Int. J. Gynaecol. Obstet. 83(1): 73-74.
Anthony, G.S., Fisher, J., Coutts, J.R.T. & Calder, A.A.
1984. The effect of exogenous hormones on the resistance of the early pregnant
human cervix. BJOG 91: 1249-1253.
Doubilet, P.M., Benson, C.B., Bourne, T. & Blaivas, M.
2014. Diagnostic criteria for nonviable pregnancy early in the first trimester. Ultrasound Quarterly 30: 3-9.
Egarter, C., Lederhilger, J., Kurz, C., Karas, H. &
Reisenberger, K. 1995a. Gemeprost for first trimester missed abortion. Arch. Gynecol. Obstet. 256(1): 29-32.
Eiben, B., Bartels, I., Bahr-Porsch, S., Borgmann, S., Gatz,
G., Gellert, G., Goebel, R., Hammans, W., Hentemann, M., O’smers, R., Rauskolb,
R. & Hansmann, I. 1990. Cytogenetic analysis of 750 spontaneous abortions
with the direct-preparation method of chorionic villi and its implications for
studying genetic causes of pregnancy wastage. Am. J. Hum. Genet. 47: 656-663.
Ellwood, D.A., Mitchell, M.D., Anderson, A.B.M. &
Turnbull, A.C. 1980. The in vitro production of prostanoids by the human cervix during pregnancy: Preliminary
observations. BJOG 87: 210-214.
Kim, C., Barnard, S., Neilson, J.P., Hickey, M., Vazquez,
J.C. & Dou, L. 2017. Medical treatments for incomplete miscarriage. Cochrane Database Syst. Rev. 1:
CD007223.
MacKenzie, I.Z. 1981. Prostaglandin E2 pessaries to
facilitate first trimester aspiration termination. BJOG 88: 1033-1037.
Nadarajah, R., Quek, Y.S., Kuppannan, K., Woon, S.Y. &
Jeganathan, R. 2014. A randomised controlled trial of expectant management
versus surgical evacuation of early pregnancy loss. Eur. J. Obstet. Gynecol. Reprod. Biol. 178: 35-41.
Nanda, K., Lopez, L.M., Grimes, D.A.,
Peloggia, A. & Nanda, G. 2012. Expectant care versus surgical treatment for miscarriage. Cochrane Database Syst. Rev. 3:
CD003518.
Ng, B.K., Annamalai, R., Lim, P.S., Aqmar Suraya, S., Nur
Azurah, A.G. & Muhammad Abdul Jamil, M.Y. 2015. Outpatient versus inpatient
intravaginal misoprostol for the treatment of first trimester incomplete miscarriage:
A randomised controlled trial. Arch. Gynecol. Obstet. 291(1): 105-113.
doi: 10.1007/s00404-014-3388-0.
Ngoc, N., Shochet, T., Blum, T., Hai, P., Dung, D., Nhan, T.
& Winikoff, B. 2013. Results from a study using misoprostol for management
of incomplete abortion in Vietnamese hospitals: Implications for task shifting. BMC Pregnancy and Childbirth 13: 118.
Sparrow, M., Tait, J. & Stone, P. 1998. Vaginal
dinoprostone versus oral misoprostol for predilatation of the cervix in first
trimester surgical abortion. Aust. NZ J.
Obstet. Gynaecol. 38: 64-68.
Wagner, N., Abele, H., Hoopmann, M., Grischke, E.M.,
Blumenstock, G., Wallwiener, D. & Kagan, K.O. 2011. Factors influencing the
duration of late first and second-trimester termination of pregnancy with
prostaglandin derivates. Eur. J. Obstet.
Gynecol. Reprod. Biol. 155(1): 75-78. doi: 10.1016/j.ejogrb.2010.10.019.
WHO. 2018. Medical
Management of Abortion. Geneva: World Health Organization.
Wilcox, A.J., Weinberg, C.R., O’Connor, J.F., Baird, D.D.,
Schlatterer, J.P., Canfield, R.E., Armstrong, E.G. & Nisula, B.C. 1988.
Incidence of early pregnancy loss. N.
Engl. J. Med. 319: 189-194.
*Pengarang
untuk surat-menyurat; email: zaleha@ppukm.ukm.edu.my
|